Key result
Point-of-care HbA1c testing evaluated against standard laboratory assays without reported concordance results.
Why the study?
Does point-of-care HbA1c testing using the A1Care Analyser agree with laboratory-measured HbA1c values in a hospital-based diabetic population?
Observational
Does point-of-care HbA1c testing using the A1Care Analyser agree with laboratory-measured HbA1c values in a hospital-based diabetic population?
Retrospective assessment evaluates concordance of HbA1c in a hospital diabetic population, suggesting improvements in diabetes management.
Glycated haemoglobin (HbA1c) is a key marker in the management of diabetic patients, particularly for monitoring blood sugar balance. It is widely used for the diagnosis and management of diabetes. Given the low compliance with laboratory testing frequency and the subsequent delay in treatment modification, point-of-care (POC) HbA1c testing offers an opportunity to improve diabetes management through rapid, actionable test results that can be used to determine treatment effectiveness, make therapeutic adjustments, and ensure that patients are following recommendations. The objective of our study is to evaluate the concordance between point-of-care HbA1c results and laboratory-measured HbA1c values in a hospital-based diabetic population.
No takes yet. Share an insight, caveat, or question.
Niyogushima et al. (2026) conducted an observational in Diabetes. Point-of-care HbA1c testing (A1Care Analyser) vs. Laboratory-measured HbA1c was evaluated on Concordance between point-of-care and laboratory HbA1c results. The abstract outlines the objective to evaluate concordance between point-of-care and laboratory HbA1c testing but does not report any quantitative results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: